Analisi dei risultati di uno studio multicentrico Italiano su efficacia e tollerabilita di fluconazolo 100 mg/die nel trattamento delle micosi cutanee

Translated title of the contribution: Analysis of the results of an Italian multicenter study of the efficacy and tolerability of fluconazole 100 mg/day in the treatment of cutaneous mycoses

P. L. Amerio, F. Cecchini, A. Bonci, R. Licastro Cicero, T. Cainelli, M. Rozzoni, G. Imberti, O. Cervetti, M. Forte, R. De Marchi, G. Bossi, A. Offidani, A. Cellini, O. Simonetti, A. Rebora, M. Guarrera, F. Rongioletti, P. Santoianni, M. Scalvenzi, A. CalifanoA. Virgili

Research output: Contribution to journalArticle

Abstract

The paper analyses data from 240 patients with dermatomycoses (T. corporis, T. cruris, T. pedis, T. unguium, P. versicolor) and others enrolled in a multicentre open study. A summary of the clinical and mycological efficacy and tolerability data of fluconazole 100 mg/day is presented. A total of 218 patients were evaluated for efficacy. The main clinical diagnoses were T. corporis (89 patients), T. cruris (53 patients) and T. pedis (46 patients). The main mycological diagnoses were the following: T. rubrum (67 cases), M. canis (41 cases), T. mentagrophytes (35 cases) and E. floccosum (32 cases). Clinical cure was observed in 179 patients (82.1%) and improvement in 21 patients (9.6%) whilst treatment failed in 11 cases (5.0%) and 5 patients (2.3%) had a relapse (data were missing for 2 patients). The average treatment duration was 20.2 days (±7.7). Clinical symptoms (erythema, itching, burning, scaling, exudation) significantly improved after 7 days of treatment in all diagnoses groups. Total disappearance of symptoms was observed in 78 to 97% of cases evaluated at the end of treatment, 93-97% and 95-99% of cases evaluated at the follow-up visits scheduled 4 and 8 weeks after the end of treatment, respectively. Eradication of the baseline pathogen was achieved in 189 patients (86.7%) whilst persistence, superinfection and relapse were reported in 20 (9.2%), 3 (1.4%) and 2 (0.9%) subjects, respectively (data missing for 4 patients). Clinical efficacy was combined with a low incidence of adverse events (12.5%), usually transient and mild and that led to treatment discontinuation in only 2 cases. Adverse events were primarily related to the gastrointestinal system (10 patients, 4.1%).

Original languageItalian
Pages (from-to)651-658
Number of pages8
JournalGiornale Italiano di Dermatologia e Venereologia
Volume134
Issue number6
Publication statusPublished - 1999

Fingerprint

Mycoses
Fluconazole
Multicenter Studies
Skin
Therapeutics
Dermatomycoses
Recurrence
Superinfection
Erythema
Pruritus

ASJC Scopus subject areas

  • Dermatology

Cite this

Amerio, P. L., Cecchini, F., Bonci, A., Licastro Cicero, R., Cainelli, T., Rozzoni, M., ... Virgili, A. (1999). Analisi dei risultati di uno studio multicentrico Italiano su efficacia e tollerabilita di fluconazolo 100 mg/die nel trattamento delle micosi cutanee. Giornale Italiano di Dermatologia e Venereologia, 134(6), 651-658.

Analisi dei risultati di uno studio multicentrico Italiano su efficacia e tollerabilita di fluconazolo 100 mg/die nel trattamento delle micosi cutanee. / Amerio, P. L.; Cecchini, F.; Bonci, A.; Licastro Cicero, R.; Cainelli, T.; Rozzoni, M.; Imberti, G.; Cervetti, O.; Forte, M.; De Marchi, R.; Bossi, G.; Offidani, A.; Cellini, A.; Simonetti, O.; Rebora, A.; Guarrera, M.; Rongioletti, F.; Santoianni, P.; Scalvenzi, M.; Califano, A.; Virgili, A.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 134, No. 6, 1999, p. 651-658.

Research output: Contribution to journalArticle

Amerio, PL, Cecchini, F, Bonci, A, Licastro Cicero, R, Cainelli, T, Rozzoni, M, Imberti, G, Cervetti, O, Forte, M, De Marchi, R, Bossi, G, Offidani, A, Cellini, A, Simonetti, O, Rebora, A, Guarrera, M, Rongioletti, F, Santoianni, P, Scalvenzi, M, Califano, A & Virgili, A 1999, 'Analisi dei risultati di uno studio multicentrico Italiano su efficacia e tollerabilita di fluconazolo 100 mg/die nel trattamento delle micosi cutanee', Giornale Italiano di Dermatologia e Venereologia, vol. 134, no. 6, pp. 651-658.
Amerio, P. L. ; Cecchini, F. ; Bonci, A. ; Licastro Cicero, R. ; Cainelli, T. ; Rozzoni, M. ; Imberti, G. ; Cervetti, O. ; Forte, M. ; De Marchi, R. ; Bossi, G. ; Offidani, A. ; Cellini, A. ; Simonetti, O. ; Rebora, A. ; Guarrera, M. ; Rongioletti, F. ; Santoianni, P. ; Scalvenzi, M. ; Califano, A. ; Virgili, A. / Analisi dei risultati di uno studio multicentrico Italiano su efficacia e tollerabilita di fluconazolo 100 mg/die nel trattamento delle micosi cutanee. In: Giornale Italiano di Dermatologia e Venereologia. 1999 ; Vol. 134, No. 6. pp. 651-658.
@article{fa527eb601e848e2adf86cd35f761121,
title = "Analisi dei risultati di uno studio multicentrico Italiano su efficacia e tollerabilita di fluconazolo 100 mg/die nel trattamento delle micosi cutanee",
abstract = "The paper analyses data from 240 patients with dermatomycoses (T. corporis, T. cruris, T. pedis, T. unguium, P. versicolor) and others enrolled in a multicentre open study. A summary of the clinical and mycological efficacy and tolerability data of fluconazole 100 mg/day is presented. A total of 218 patients were evaluated for efficacy. The main clinical diagnoses were T. corporis (89 patients), T. cruris (53 patients) and T. pedis (46 patients). The main mycological diagnoses were the following: T. rubrum (67 cases), M. canis (41 cases), T. mentagrophytes (35 cases) and E. floccosum (32 cases). Clinical cure was observed in 179 patients (82.1{\%}) and improvement in 21 patients (9.6{\%}) whilst treatment failed in 11 cases (5.0{\%}) and 5 patients (2.3{\%}) had a relapse (data were missing for 2 patients). The average treatment duration was 20.2 days (±7.7). Clinical symptoms (erythema, itching, burning, scaling, exudation) significantly improved after 7 days of treatment in all diagnoses groups. Total disappearance of symptoms was observed in 78 to 97{\%} of cases evaluated at the end of treatment, 93-97{\%} and 95-99{\%} of cases evaluated at the follow-up visits scheduled 4 and 8 weeks after the end of treatment, respectively. Eradication of the baseline pathogen was achieved in 189 patients (86.7{\%}) whilst persistence, superinfection and relapse were reported in 20 (9.2{\%}), 3 (1.4{\%}) and 2 (0.9{\%}) subjects, respectively (data missing for 4 patients). Clinical efficacy was combined with a low incidence of adverse events (12.5{\%}), usually transient and mild and that led to treatment discontinuation in only 2 cases. Adverse events were primarily related to the gastrointestinal system (10 patients, 4.1{\%}).",
keywords = "Dermatomycoses, Fluconazole therapeutic use, Tinea",
author = "Amerio, {P. L.} and F. Cecchini and A. Bonci and {Licastro Cicero}, R. and T. Cainelli and M. Rozzoni and G. Imberti and O. Cervetti and M. Forte and {De Marchi}, R. and G. Bossi and A. Offidani and A. Cellini and O. Simonetti and A. Rebora and M. Guarrera and F. Rongioletti and P. Santoianni and M. Scalvenzi and A. Califano and A. Virgili",
year = "1999",
language = "Italian",
volume = "134",
pages = "651--658",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - Analisi dei risultati di uno studio multicentrico Italiano su efficacia e tollerabilita di fluconazolo 100 mg/die nel trattamento delle micosi cutanee

AU - Amerio, P. L.

AU - Cecchini, F.

AU - Bonci, A.

AU - Licastro Cicero, R.

AU - Cainelli, T.

AU - Rozzoni, M.

AU - Imberti, G.

AU - Cervetti, O.

AU - Forte, M.

AU - De Marchi, R.

AU - Bossi, G.

AU - Offidani, A.

AU - Cellini, A.

AU - Simonetti, O.

AU - Rebora, A.

AU - Guarrera, M.

AU - Rongioletti, F.

AU - Santoianni, P.

AU - Scalvenzi, M.

AU - Califano, A.

AU - Virgili, A.

PY - 1999

Y1 - 1999

N2 - The paper analyses data from 240 patients with dermatomycoses (T. corporis, T. cruris, T. pedis, T. unguium, P. versicolor) and others enrolled in a multicentre open study. A summary of the clinical and mycological efficacy and tolerability data of fluconazole 100 mg/day is presented. A total of 218 patients were evaluated for efficacy. The main clinical diagnoses were T. corporis (89 patients), T. cruris (53 patients) and T. pedis (46 patients). The main mycological diagnoses were the following: T. rubrum (67 cases), M. canis (41 cases), T. mentagrophytes (35 cases) and E. floccosum (32 cases). Clinical cure was observed in 179 patients (82.1%) and improvement in 21 patients (9.6%) whilst treatment failed in 11 cases (5.0%) and 5 patients (2.3%) had a relapse (data were missing for 2 patients). The average treatment duration was 20.2 days (±7.7). Clinical symptoms (erythema, itching, burning, scaling, exudation) significantly improved after 7 days of treatment in all diagnoses groups. Total disappearance of symptoms was observed in 78 to 97% of cases evaluated at the end of treatment, 93-97% and 95-99% of cases evaluated at the follow-up visits scheduled 4 and 8 weeks after the end of treatment, respectively. Eradication of the baseline pathogen was achieved in 189 patients (86.7%) whilst persistence, superinfection and relapse were reported in 20 (9.2%), 3 (1.4%) and 2 (0.9%) subjects, respectively (data missing for 4 patients). Clinical efficacy was combined with a low incidence of adverse events (12.5%), usually transient and mild and that led to treatment discontinuation in only 2 cases. Adverse events were primarily related to the gastrointestinal system (10 patients, 4.1%).

AB - The paper analyses data from 240 patients with dermatomycoses (T. corporis, T. cruris, T. pedis, T. unguium, P. versicolor) and others enrolled in a multicentre open study. A summary of the clinical and mycological efficacy and tolerability data of fluconazole 100 mg/day is presented. A total of 218 patients were evaluated for efficacy. The main clinical diagnoses were T. corporis (89 patients), T. cruris (53 patients) and T. pedis (46 patients). The main mycological diagnoses were the following: T. rubrum (67 cases), M. canis (41 cases), T. mentagrophytes (35 cases) and E. floccosum (32 cases). Clinical cure was observed in 179 patients (82.1%) and improvement in 21 patients (9.6%) whilst treatment failed in 11 cases (5.0%) and 5 patients (2.3%) had a relapse (data were missing for 2 patients). The average treatment duration was 20.2 days (±7.7). Clinical symptoms (erythema, itching, burning, scaling, exudation) significantly improved after 7 days of treatment in all diagnoses groups. Total disappearance of symptoms was observed in 78 to 97% of cases evaluated at the end of treatment, 93-97% and 95-99% of cases evaluated at the follow-up visits scheduled 4 and 8 weeks after the end of treatment, respectively. Eradication of the baseline pathogen was achieved in 189 patients (86.7%) whilst persistence, superinfection and relapse were reported in 20 (9.2%), 3 (1.4%) and 2 (0.9%) subjects, respectively (data missing for 4 patients). Clinical efficacy was combined with a low incidence of adverse events (12.5%), usually transient and mild and that led to treatment discontinuation in only 2 cases. Adverse events were primarily related to the gastrointestinal system (10 patients, 4.1%).

KW - Dermatomycoses

KW - Fluconazole therapeutic use

KW - Tinea

UR - http://www.scopus.com/inward/record.url?scp=0033390152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033390152&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0033390152

VL - 134

SP - 651

EP - 658

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 6

ER -